NovaBridge Biosciences annual return on equity
2020
2021
2022
2023
2024
2025
NovaBridge Biosciences Return on Equity (ROE) Growth & History (NBP)
NovaBridge Biosciences's return on equity was −21.42% for fiscal 2025.
View full NovaBridge Biosciences company overviewNovaBridge Biosciences annual return on equity history
| Fiscal year | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −21.42% | −11.40 pp |
| 2024 | 2024-12-31 | −10.02% | +52.89 pp |
| 2023 | 2023-12-31 | −62.91% | +2.59 pp |
| 2022 | 2022-12-31 | −65.50% | −19.12 pp |
| 2021 | 2021-12-31 | −46.38% | −71.70 pp |
| 2020 | 2020-12-31 | 25.32% | — |
NovaBridge Biosciences quarterly return on equity
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
| Fiscal quarter | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| Q4 2025 | 2025-12-31 | −12.57% | −8.49 pp |
| Q3 2025 | 2025-09-30 | −3.00% | — |
| Q2 2025 | 2025-06-30 | −2.79% | — |
| Q1 2025 | 2025-03-31 | −1.58% | — |
| Q4 2024 | 2024-12-31 | −4.08% | — |
NovaBridge Biosciences return on equity trends
Over the last five fiscal years, NovaBridge Biosciences's return on equity decreased from 25.32% to −21.42%, a change of −46.73 percentage points. The latest reported quarter, Q4 2025, shows −12.57%.
About the metric
What return on equity (ROE) means
Return on equity (ROE) measures how much net income a company generates relative to shareholders’ equity. It can help evaluate how efficiently equity capital is used, but unusually high or negative values may reflect leverage, losses, or a small equity base.
Calculation and source
How return on equity is calculated
TickerStat calculates ROE as SEC-reported net income divided by average stockholders’ equity at the beginning and end of the fiscal period. Periods with missing or non-positive average equity are omitted. Quarterly ROE uses quarterly net income and is not annualized. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review NovaBridge Biosciences source filings ↗